title: ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
abstract: This part of the EFISG guidelines focuses on non-neutropenic adult patients. Only a few of the numerous recommendations can be summarized in the abstract. Prophylactic usage of fluconazole is supported in patients with recent abdominal surgery and recurrent gastrointestinal perforations or anastomotic leakages. Candida isolation from respiratory secretions alone should never prompt treatment. For the targeted initial treatment of candidaemia, echinocandins are strongly recommended while liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength. Treatment duration for candidaemia should be a minimum of 14 days after the end of candidaemia, which can be determined by one blood culture per day until negativity. Switching to oral treatment after 10 days of intravenous therapy has been safe in stable patients with susceptible Candida species. In candidaemia, removal of indwelling catheters is strongly recommended. If catheters cannot be removed, lipid-based amphotericin B or echinocandins should be preferred over azoles. Transoesophageal echocardiography and fundoscopy should be performed to detect organ involvement. Native valve endocarditis requires surgery within a week, while in prosthetic valve endocarditis, earlier surgery may be beneficial. The antifungal regimen of choice is liposomal amphotericin B +/- flucytosine. In ocular candidiasis, liposomal amphotericin B +/- flucytosine is recommended when the susceptibility of the isolate is unknown, and in susceptible isolates, fluconazole and voriconazole are alternatives. Amphotericin B deoxycholate is not recommended for any indication due to severe side effects.
authors.affiliation: Department I of Internal Medicine, Clinical Trials Centre Cologne, ZKS Köln, BMBF 01KN1106, Center for Integrated Oncology CIO KölnBonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany. oliver.cornely@ctuc.de
authors.forename: O A
authors.initials: OA
authors.lastname: Cornely
authors.forename: M
authors.initials: M
authors.lastname: Bassetti
authors.forename: T
authors.initials: T
authors.lastname: Calandra
authors.forename: J
authors.initials: J
authors.lastname: Garbino
authors.forename: B J
authors.initials: BJ
authors.lastname: Kullberg
authors.forename: O
authors.initials: O
authors.lastname: Lortholary
authors.forename: W
authors.initials: W
authors.lastname: Meersseman
authors.forename: M
authors.initials: M
authors.lastname: Akova
authors.forename: M C
authors.initials: MC
authors.lastname: Arendrup
authors.forename: S
authors.initials: S
authors.lastname: Arikan-Akdagli
authors.forename: J
authors.initials: J
authors.lastname: Bille
authors.forename: E
authors.initials: E
authors.lastname: Castagnola
authors.forename: M
authors.initials: M
authors.lastname: Cuenca-Estrella
authors.forename: J P
authors.initials: JP
authors.lastname: Donnelly
authors.forename: A H
authors.initials: AH
authors.lastname: Groll
authors.forename: R
authors.initials: R
authors.lastname: Herbrecht
authors.forename: W W
authors.initials: WW
authors.lastname: Hope
authors.forename: H E
authors.initials: HE
authors.lastname: Jensen
authors.forename: C
authors.initials: C
authors.lastname: Lass-Flörl
authors.forename: G
authors.initials: G
authors.lastname: Petrikkos
authors.forename: M D
authors.initials: MD
authors.lastname: Richardson
authors.forename: E
authors.initials: E
authors.lastname: Roilides
authors.forename: P E
authors.initials: PE
authors.lastname: Verweij
authors.forename: C
authors.initials: C
authors.lastname: Viscoli
authors.forename: A J
authors.initials: AJ
authors.lastname: Ullmann
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D019317:Evidence-Based Medicine; D006801:Humans
chemical_list: D000935:Antifungal Agents